CLINICAL TRIALS PROFILE FOR MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
✉ Email this page to a colleague
All Clinical Trials for MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01906528 ↗ | Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium | Completed | Oslo University Hospital | Phase 1 | 2013-03-01 | Muscle relaxants are drugs providing muscle relaxation during surgical treatment. Previous studies have shown that males and females respond differently to this kind of drug. Our hypothesis is that males are more sensitive to the effect of Mivacurium (a muscle relaxant) than females, meaning that males need a lower blood concentration of the drug than females in order to obtain a given effect. |
NCT01906528 ↗ | Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium | Completed | University of California, San Francisco | Phase 1 | 2013-03-01 | Muscle relaxants are drugs providing muscle relaxation during surgical treatment. Previous studies have shown that males and females respond differently to this kind of drug. Our hypothesis is that males are more sensitive to the effect of Mivacurium (a muscle relaxant) than females, meaning that males need a lower blood concentration of the drug than females in order to obtain a given effect. |
NCT02117401 ↗ | A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery Patients | Completed | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Phase 4 | 2012-01-01 | To evaluate the effect and safety of mivacurium chloride in pediatric patients. |
NCT02473601 ↗ | Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis | Unknown status | Jiangsu Nhwa Pharmaceutical Co., Ltd. | Phase 2 | 2014-10-01 | Observed the muscle relaxation of mivacurium in patients with liver cirrhosis.Clear of mivacurium in patients with liver cirrhosis without muscle relaxant accumulation and delayed recovery phenomenon |
NCT02473601 ↗ | Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis | Unknown status | Tang-Du Hospital | Phase 2 | 2014-10-01 | Observed the muscle relaxation of mivacurium in patients with liver cirrhosis.Clear of mivacurium in patients with liver cirrhosis without muscle relaxant accumulation and delayed recovery phenomenon |
NCT02664142 ↗ | BIS Monitoring of the Depth of Anaesthesia in Children | Completed | University Hospital Ostrava | N/A | 2015-06-01 | General anaesthesia (GA) is, according to many definitions, the greatest gift presented to the medical art (S. B. Nuland). One of the aims of GA is to achieve the optimal depth of anaesthesia and rapid emergence from general anaesthesia. In order to achieve this goal, it is necessary to observe the clinical condition of the patient, and at the same time monitor the patient's overall condition. With the currently available options of GA management (e.g. use of intravenous anaesthetics, strong analgesics and modern volatile anaesthetics, in combination with various methods of topical anaesthesia) the importance of methods measuring the depth of GA increases. The depth of GA may be defined as a continuous progressive decreasing of the central nervous system, together with a decreased reactivity to stimuli. In the course of GA, perioperative awareness is detected in 0.1-0.2% of cases. Awakening during a surgical procedure may result in significant psychological complications (e.g. post-traumatic stress disorder), and the patient may suffer from a serious long-time disorder. |
NCT03019835 ↗ | Can we Antagonize Mivacurium With Neostigmine ? | Completed | Université Libre de Bruxelles | N/A | 2016-12-01 | The antagonism of neuromuscular blocking agents (NMBA) (or curares), as well as the antagonism of other drugs used in anesthesia, is a major challenge for the speciality. Residual paralysis is indeed a risk factor for post-operative morbidity and mortality and antagonization of curares at the end of the procedure is associated with a reduction in mortality . Its use should be as large as possible and its contraindications are extremely rare. The antagonism of the NMBA reduces the duration of the neuromuscular block and the complications that are associated . In this study, the investigators use mivacurium (or Mivacron) as non-depolarizing curare and neostigmine as an antagonist. Neostigmine reduces the duration of the neuromuscular block induced by mivacurium, By reducing the breakdown of acetylcholine, neostigmine induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade. But the use of neostigmine in current practice is not very widespread in this clinical situation. The reduction in the duration of the block is significant in comparison with a spontaneous recovery . Moreover, spontaneous recovery is not always complete and sometimes very long. Nevertheless, its action is effective and this study could support this use but also specify the duration and the quality of the return to normal of the neuromuscular transmission. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
Condition Name
Clinical Trial Locations for MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
Trials by Country
Clinical Trial Progress for MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase
Clinical Trial Sponsors for MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor Name